Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
| 1 | Acute myeloid leukemia |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 2 | AGE-RAGE signaling pathway in diabetic complications |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 3 | Axon guidance |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 4 | Bladder cancer |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 5 | Breast cancer |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 6 | Calcium signaling pathway |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 7 | Cell cycle |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 8 | Central carbon metabolism in cancer |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 9 | Choline metabolism in cancer |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 10 | Chronic myeloid leukemia |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 11 | EGFR tyrosine kinase inhibitor resistance |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 12 | Endocytosis |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 13 | ErbB signaling pathway |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 14 | Fluid shear stress and atherosclerosis |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 15 | Focal adhesion |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 16 | Gap junction |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 17 | Glioma |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 18 | Hematopoietic cell lineage |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 19 | HIF-1 signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 20 | Human cytomegalovirus infection |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 21 | Human papillomavirus infection |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 22 | JAK-STAT signaling pathway |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 23 | Kaposi sarcoma-associated herpesvirus infection |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 24 | MAPK signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 25 | Melanogenesis |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 26 | Melanoma |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 27 | MicroRNAs in cancer |
[2] ABL1, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 28 | Neurotrophin signaling pathway |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 29 | Pancreatic cancer |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 30 | Pathogenic Escherichia coli infection |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 31 | Pathways in cancer |
[3] ABL1, KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 32 | Phospholipase D signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 33 | PI3K-Akt signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 34 | Prostate cancer |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 35 | Proteoglycans in cancer |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 36 | Rap1 signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 37 | Ras signaling pathway |
[3] ABL1, KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| [1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
| 38 | Regulation of actin cytoskeleton |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 39 | Relaxin signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 40 | Renal cell carcinoma |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 41 | Rheumatoid arthritis |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 42 | Shigellosis |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 | |||||
| 43 | VEGF signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 44 | Viral myocarditis |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |